activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody
/ Benhealth Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 03, 2019
Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer
(clinicaltrials.gov)
- P2; N=80; Recruiting; Sponsor: Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.; Trial completion date: Dec 2019 ➔ Dec 2020; Trial primary completion date: Dec 2019 ➔ Dec 2020
Clinical • Trial completion date • Trial primary completion date
1 to 1
Of
1
Go to page
1